Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.58 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 0.58 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.55 |
| ▸ | NQO2 | P16083 | 11/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142092 | 0.98 | NQO2 (0.57) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL23566023 | 0.96 | NQO2 (0.55) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL14089900 | 0.90 | NQO2 (0.49) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL23566324 | 0.88 | NQO2 (0.47) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL14089897 | 0.85 | NQO2 (0.55) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL14599571 | 0.85 | NQO2 (0.66) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL399197 | 0.81 | KIF11 (0.48) | PTPN1PTPN11 | |
| SCHEMBL23566338 | 0.81 | NQO2 (0.41) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| SCHEMBL23566337 | 0.81 | NQO2 (0.41) | TOP2ATOP2BNQO2PRMT1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6753847 | 0.79 | TAAR1 (0.59) | ALDH1A1HPGDHSD17B10PTPN1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-7410999-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINIA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410989-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | The University of North Carolina at Chapel Hill: | 2008-03-06 | — | — | US | disclosed |
| EP-1399163-B1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1837024-A2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7241795-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070072877-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-7183286-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-02-27 | — | — | US | disclosed |
| US-7163955-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-11 | — | — | US | disclosed |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-23 | — | — | US | disclosed |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-25 | — | — | US | disclosed |
| US-6737440-B2 | 2,5-BIS ((ALKYL (OR ARYL) IMINO) AMINOPHENYL) FURANS, THIOPHENES OR PYRROLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-05-18 | — | — | US | disclosed |
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-23 | — | — | US | disclosed |
| EP-1337510-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC \"REVERSED AMIDINES\ | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | GEORGIA STATE UNIVERSITY | 2003-05-01 | — | — | US | disclosed |
| WO-2002057224-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC 'REVERSED AMIDINES' | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | TOP2A 1507/4885TOP2B 1119/4885TOP1 1403/4885 |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | HRH4, TLR7, DDAH1 | TOP2A 1733/4885TOP2B 1016/4885TOP1 1681/4885 |
| US-20040235927-A1 | Synthesis and antimicrobial activity of novel dicationic \"reversed amidines\ | HRH4, HDHD5, MRPS7 | TOP2A 2194/4885TOP2B 1423/4885TOP1 2272/4885 |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | TOP2A 1507/4885TOP2B 1119/4885TOP1 1403/4885 |
| US-20060063931-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | TOP2A 1507/4885TOP2B 1119/4885TOP1 1403/4885 |
| US-20070010533-A1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | OAT, GYS2, HCCS | TOP2A 1507/4885TOP2B 1119/4885TOP1 1403/4885 |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | TLR7, DHRS9, TLR8 | TOP2A 3113/4885TOP2B 2313/4885TOP1 2698/4885 |
| US-20070072877-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | TOP2A 1507/4885TOP2B 1119/4885TOP1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.